Insider · CIK 0001103780
Christopher Bunka
Files at LEXX (Lexaria Bioscience Corp.). First filing Jul 30, 2025, latest Jul 30, 2025.
In brief
Christopher Bunka files SEC Form 4 as director and CEO at LEXX (Lexaria Bioscience Corp.). Since Jul 30, 2025, Christopher Bunka has reported 1 open-market buy worth $25k and 0 open-market sells worth $0, the latest filed on Jul 30, 2025.
A track record needs three past buys with six months of prices behind them; Christopher Bunka has 0, so none is measured yet.
The newest scored trade: bought $25k of LEXX on Jul 29, 2025, filed Jul 30, 2025, scored 56 (moderate).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
LEXX: Lexaria Bioscience Corp.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 56Moderate | Lexaria Bioscience Corp. | $25k 27,500 shares | +11% | +9% from low-75% from high |
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 17, 2026 | LEXX Lexaria Bioscience Corp. | GGift common shares | -100,000 | $0.00 | $0 | 273,543 | Mar 18, 2026 |
| Jul 29, 2025 | LEXX Lexaria Bioscience Corp. | POpen-market purchase common sharesindirect: Private Holding Company | +15,600 | $0.92 | $14k | 270,012 | Jul 30, 2025 |
| Jul 30, 2025 | LEXX Lexaria Bioscience Corp. | POpen-market purchase common sharesindirect: Private Holding Company | +11,900 | $0.91 | $11k | 281,912 | Jul 30, 2025 |
| May 15, 2025 | LEXX Lexaria Bioscience Corp. | AGrant or award Stock Optionsderivative | +11,000 | $0.00 | $0 | 184,834 | May 16, 2025 |
| Jan 7, 2025 | LEXX Lexaria Bioscience Corp. | AGrant or award Restricted Stock Award | +100,000 | $0.00 | $0 | 373,543 | Jan 10, 2025 |
| Apr 26, 2024 | LEXX Lexaria Bioscience Corp. | AGrant or award Stock Optionsderivative | +49,500 | $0.00 | $0 | 180,501 | May 10, 2024 |
| Oct 26, 2023 | LEXX Lexaria Bioscience Corp. | AGrant or award Stock Optionsderivative | +30,000 | $0.00 | $0 | 131,001 | Oct 30, 2023 |
Questions about Christopher Bunka
Answered from the filings on this page, as of the latest one.
Is Christopher Bunka buying or selling?
Not in the last 12 months. Christopher Bunka's latest open-market trade on SEC Form 4 was bought $25k of LEXX on Jul 29, 2025.
How did Christopher Bunka's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Christopher Bunka has 0.
Where does Christopher Bunka file Form 4?
Christopher Bunka has filed Form 4 at LEXX (Lexaria Bioscience Corp.) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.